文献速递肝病

Resmetirom治疗MASH F2-F3纤维化患者:MAESTRO-NASH 3期试验的事后分析

Clinical Trial: Phase 3 Trial of Resmetirom Versus Placebo in Metabolic Dysfunction-Associated Steatohepatitis-Reanalysis of Fibrosis Stage 2-3 Subset.
PubMed 文献 · Aliment Pharmacol Ther · 2026-07-29

MAESTRO-NASH 3期试验事后分析纳入917例F2或F3纤维化MASH患者,评估resmetirom 80mg或100mg与安慰剂的52周疗效。结果显示,resmetirom组MASH缓解率和纤维化改善率均显著高于安慰剂,且LDL-C显著降低,安全性无新信号。

要点

  • MASH缓解率:80mg组25.7%、100mg组29.9%,均显著高于安慰剂组9.5%(p<0.0001)。
  • 纤维化改善率:80mg组26.5%、100mg组28.9%,均显著高于安慰剂组17.3%(p<0.01)。
  • 24周LDL-C变化:80mg组降11.7%、100mg组降13.7%,安慰剂组升2.3%(p<0.0001)。

核心结论

  • 在F2或F3纤维化MASH患者中,resmetirom 52周治疗有效且安全,结果与主要分析人群一致。

研究设计与样本

  • MAESTRO-NASH 3期随机对照试验的事后分析,纳入917例F2或F3纤维化MASH患者,比较resmetirom 80mg、100mg与安慰剂每日口服52周。

主要发现

  • MASH缓解率:80mg组25.7%、100mg组29.9%、安慰剂组9.5%(与安慰剂比较均p<0.0001)。
  • 纤维化改善率:80mg组26.5%、100mg组28.9%、安慰剂组17.3%(与安慰剂比较均p<0.01)。
  • 24周LDL-C变化:80mg组降11.7%、100mg组降13.7%,安慰剂组升2.3%(与安慰剂比较均p<0.0001)。
  • 代谢危险因素患病率高:高血压78.0%、血脂异常71.1%、2型糖尿病67.0%。
  • 未发现新的安全性信号。

关键数值与推荐

  • MASH缓解定义:肝细胞气球样变评分0、小叶炎症评分≤1、NAS较基线降低≥2分且纤维化无恶化。
  • 纤维化改善定义:纤维化分期改善≥1级且NAS无恶化(第52周)。

临床怎么用

  • 对于F2或F3纤维化MASH患者,resmetirom 80mg或100mg每日口服可考虑用于改善MASH缓解和纤维化。

局限性

  • 为事后分析,非预设主要分析。
  • 未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Resmetirom is an oral thyroid hormone receptor beta agonist clinically used to treat metabolic dysfunction-associated steatohepatitis (MASH) among adults with stage F2 or F3 fibrosis. AIMS: Because the pivotal, 52-week, randomized, controlled, phase 3 MAESTRO-NASH trial (once-daily oral resmetirom 80 or 100 mg or placebo) included patients with F1, F2, or F3 fibrosis, we conducted a post hoc analysis aimed at assessing treatment response in the subset of patients with stages F2 and F3 fibrosis, consistent with the approved label population. METHODS: Co-primary end points were MASH resolution (hepatocellular ballooning score 0, lobular inflammation score ≤ 1, and ≥ 2-point nonalcoholic fatty liver disease activity score [NAS] reduction from baseline) with no fibrosis worsening, and ≥ 1-stage fibrosis improvement with no NAS worsening at Week 52. RESULTS: Among 917 patients with F2 or F3 fibrosis, metabolic risk factor prevalence was high (hypertension, 78.0%; dyslipidemia, 71.1%; type 2 diabetes, 67.0%). MASH resolution was achieved by 25.7% in the 80-mg group, 29.9% in the 100-mg group, and 9.5% in the placebo group (p < 0.0001 for both comparisons with placebo). Respective percentages with fibrosis improvement were 26.5%, 28.9%, and 17.3% (p < 0.01 for both comparisons). From baseline to Week 24, low-density lipoprotein cholesterol decreased by 11.7% and 13.7% in the 80- and 100-mg resmetirom groups, respectively, and increased by 2.3% with placebo (p < 0.0001 for both comparisons). No new safety signals emerged. CONCLUSION: Results among patients with F2 and F3 fibrosis were consistent with the primary MAESTRO-NASH analysis population, demonstrating efficacy and safety of resmetirom after 52 weeks.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Mironova M, Padmanabhan K, Schneider D, et al. Clinical Trial: Phase 3 Trial of Resmetirom Versus Placebo in Metabolic Dysfunction-Associated Steatohepatitis-Reanalysis of Fibrosis Stage 2-3 Subset. Aliment Pharmacol Ther. 2026. PMID: 42527732. doi:10.1111/apt.70888

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。